![Magnair™ an eFlow® Closed System Nebulizer together with Sunovion's Lonhala™ is the first eFlow technology based product to receive FDA Approval to Treat Chronic Obstructive Pulmonary Disease (COPD) Magnair™ an eFlow® Closed System Nebulizer together with Sunovion's Lonhala™ is the first eFlow technology based product to receive FDA Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)](https://mma.prnewswire.com/media/616445/PARI_Pharma_Lonhala_Magnair_Inhalation_Solution.jpg?p=facebook)
Magnair™ an eFlow® Closed System Nebulizer together with Sunovion's Lonhala™ is the first eFlow technology based product to receive FDA Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)
![LAMIRA®, an eFlow® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE® (amikacin liposome inhalation suspension) LAMIRA®, an eFlow® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE® (amikacin liposome inhalation suspension)](https://mma.prnewswire.com/media/1472397/eFlow_Partnering_eBase_Controller_Lamira.jpg?p=facebook)
LAMIRA®, an eFlow® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE® (amikacin liposome inhalation suspension)
![A schematic of the aerosol production within the eFlow® nebulizer system | Download Scientific Diagram A schematic of the aerosol production within the eFlow® nebulizer system | Download Scientific Diagram](https://www.researchgate.net/publication/260316896/figure/fig5/AS:282615488761912@1444392191690/A-schematic-of-the-aerosol-production-within-the-eFlowR-nebulizer-system.png)